Based on promising results of a phase II trial evaluating FAK inhibitors for recurrent or advanced NF2 mutation-positive intracranial meningiomas, which demonstrated PFS of 83% for WHO grade 1 and 33% for grade 2/3 patients at 6 months [33], further evaluation of FAK inhibitor for malignant perineurioma and ectopic meningioma is desired. The gene discussed is NF2; the disease is meningioma.